UroXatral

In an article, we recently published in Molecular Ecology (Benestan et al. 2015) and we documented fine-scale population… (More)

Benign prostate hyperplasia (BPH) occurs in up to 50% of men by age 50, and the incidence increases with age. This common… (More)

AIM To assess differences in pupil diameter between men taking systemic α(1)-adrenoreceptor antagonists and controls. SETTING… (More)

Alfuzosin, a selective alpha-1a antagonistis is the most recently approved AARAS, with limited cardiac toxicity and exclusively… (More)

OBJECTIVE Assess safety and efficacy of 10-mg prolonged-release alfuzosin (Xatral XL) in benign prostatic hyperplasia (BPH… (More)

In their paper on the intraoperative floppy iris syndrome (IFIS), Chang and Campbell raise awareness of an important clinical… (More)

 

alpha-adrenoceptor antagonists have traditionally been used in the treatment of hypertension but in recent years they have become… (More)

Approximately 25% of men over 40 or 50 suffer from lower urinary tract symptoms (LUTS) caused by benign prostatic hyperplasia… (More)